摘要
肺癌是目前发病率和死亡率较高的恶性肿瘤,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占肺癌总体患者的85%。因肺癌的异质性及患者的个体差异,多数患者在发现时已属晚期,早期患者可以采取手术治疗和术后辅助治疗。晚期患者的生存期有限,传统的放化疗能适当延长部分患者的寿命。随着分子检测技术的进步,越来越多肺癌驱动基因被发现。发现可靶向的驱动基因并一线使用相应的靶向药物治疗成为目前NSCLC治疗的最新共识。RAS基因的研究近年来日益受到人们的关注,其作为NSCLC中的突变靶点,有25%至33%的突变率,在肿瘤形成和细胞增殖分化调控中起着重要的作用。本文对NSCLC患者中发生RAS突变人群的治疗效果及预后情况的相关研究进展进行综述,以期为临床治疗、科学研究提供更多资料。
Lung cancer is a malignant tumor with high morbidity and mortality. NSCLC accounts for 85 percent of the total patients with lung cancer. Because of the heterogeneity of lung cancer and the difference in individuals, most patients have been in the late stage when they were confirmed. Early stage patients can be treated with surgery and postoperative adjuvant therapy. Traditional radiotherapy and chemotherapy can extend the survival of some patients to a certain extent. With the development of molecular detection, more and more lung cancer-driving genes have been discovered. The discovery of targeted driver genes and first-line treatment with corresponding drugs targeting those genes have become the latest consensus in current NSCLC therapy. Research on RAS gene has attracted increasing attention in recent years, it serves as a mutational target in NSCLC, with a mutation rate from 25% to 33%. It plays an important role in tumor formation and the regulation of cell proliferation and differentiation. The main purpose of this review is to study the therapeutic efficacy and prognosis of patients with RAS mutation in NSCLC, in order to provide more data for clinical treatment and scientific research.
作者
钱莹
毕清
Qian Ying;Bi Qing(College of Basic Medical Sciences,Yunnan Cancer Hospital&the Third Affiliated Hospital of Kunming Medical University&Yunnan Cancer Center,Kunming 650000,Yunnan,China;Third Depart-ment of Internal Medicine,Yunnan Cancer Hospital&the Third Affiliated Hospital of Kunming Medical University&Yunnan Cancer Center,Kunming 650000,Yunnan,China)
出处
《肿瘤预防与治疗》
2021年第11期1084-1089,共6页
Journal of Cancer Control And Treatment
关键词
肺肿瘤
RAS突变
疗效
生存
Lung cancer
RAS mutation
Efficacy
Survival
